Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Rucaparib (AG-014699): Precision Radiosensitization and D...
2025-09-29
Explore how Rucaparib (AG-014699, PF-01367338), a potent PARP inhibitor, advances cancer biology research through selective radiosensitization and deep modulation of DNA repair pathways. This article uniquely integrates recent insights on regulated cell death and mitochondrial signaling, providing a comprehensive resource for DNA damage response research.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Unraveling mRNA Engineering for ...
2025-09-28
Explore how EZ Cap™ Cas9 mRNA (m1Ψ) redefines genome editing by synergizing advanced mRNA engineering—Cap1 structure, N1-Methylpseudo-UTP, and poly(A) tail—for optimal stability and translation in mammalian cells. This article uniquely analyzes the interplay between mRNA modifications, nuclear export, and immune evasion for superior CRISPR-Cas9 outcomes.
-
TMCB(CK2 and ERK8 Inhibitor): Pioneering Biochemical Tool...
2025-09-27
Discover how 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid, a tetrabromo benzimidazole derivative, is revolutionizing protein interaction studies as a molecular tool for enzyme interaction and phase separation research. This article explores novel cross-disciplinary applications and mechanistic insights that set TMCB(CK2 and ERK8 inhibitor) apart from conventional biochemical reagents.
-
DRB: Unraveling Transcriptional Elongation and Phase Sepa...
2025-09-26
Explore the multifaceted role of 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) as a transcriptional elongation inhibitor in HIV research, cell cycle regulation, and emerging phase separation biology. This article uniquely connects DRB’s action on cyclin-dependent kinase signaling with the latest insights into RNA-protein condensates and translational medicine.
-
c-Myc Peptide: Driving Innovation in Immunoassay Design a...
2025-09-25
Discover how the c-Myc Peptide enhances immunoassay specificity and enables advanced studies in transcription factor regulation. This in-depth article explores novel mechanistic applications of synthetic c-Myc peptide for immunoassays, uniquely bridging cancer research with autophagy signaling insights.
-
Eltanexor (KPT-8602): Targeting XPO1 for Precision Cancer...
2025-09-24
Explore the advanced role of Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, in precision cancer research. This article uniquely dissects its mechanistic action, translational applications, and emerging insights in nuclear export modulation for hematological and colorectal malignancies.
-
Filipin III in Membrane Lipid Raft Research: Advanced Str...
2025-09-23
Explore the pivotal role of Filipin III, a cholesterol-binding fluorescent antibiotic, in advanced membrane cholesterol visualization and lipid raft research. This article details methodological innovations and practical considerations for cholesterol detection in membranes using Filipin III.
-
When added to the culture medium extracellular ATP
2025-03-03
When added to the culture medium, extracellular ATP is metabolized into adenosine by ectonucleotidases, and ARs are then activated by adenosine with concentrations in the micromolar range [27]. However, our study showed that activation of ARs by exogenous adenosine could not induce the odontoblastic
-
br Conclusion br Conflicts of interest br
2025-03-03
Conclusion Conflicts of interest Compliance with ethical standards Introduction Tuberculosis is one of the leading causes of morbidity and mortality, amongst infectious diseases. India is a high burden country for Tuberculosis. Caused by Mycobacterium tuberculosis, it Pyr3 can present a
-
It is well accepted that PKA
2025-03-03
It is well accepted that PKA is a key enzyme activated at the beginning of the capacitation process [69]. As mentioned above phosphorylation/inactivation of cofilin in sperm is a PKA dependent process [58]. We could not see any change in cofilin phosphorylation level by adding the PKA activator 8Br-
-
Introduction The lysosomal storage disorder
2025-03-03
Introduction The lysosomal storage disorder Gaucher disease (Mendelian Inheritance in Man, OMIM #230800) results from the recessively inherited deficiency of lysosomal glucocerebrosidase (GCase, EC 3.2.1.45), caused by mutations in the gene GBA1 (MIM# 606463) located on chromosome 1q21. The enzymat
-
hydroxydopamine OHDA is a selective
2025-03-03
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and
-
Renal Cell Carcinoma RCC is a lethal cancer with bad
2025-03-03
Renal Cell Carcinoma (RCC) is a lethal cancer with bad prognosis due to development of chemoresistance and recurrence of an aggressive tumor with increased tumor-angiogenesis and metastasis [7]. We have found Axl and Gas6 to be differentially presented in RCC subtypes, and Axl to correlate to tumor
-
LPA binds to six specific cell surface GPCR
2025-03-03
LPA binds to six specific cell surface GPCR receptors. The receptors LPA1 (lysophosphatidic receptor 1, formerly, Edg2), LPA2 (Edg4) and LPA3 (Edg7) belong to the endothelial differentiation gene family (EDG) and share sequence homology (50–60% amino BKT140 homology) An et al., 1997, An et al., 199
-
br Materials and methods br Results Dried
2025-03-01
Materials and methods Results Dried LDN 57444 used were 48.46 g C. benghalensis, 857.98 g T. zebrina and 25.09 g T. fluminensis. The samples gave 12.9% C. benghalensis, 0.078% T. zebrina and 3.06% T. fluminensis methanol extracts. The methanol extracts were evaluated for their lipoxygenase i